JP2017537940A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537940A5
JP2017537940A5 JP2017531478A JP2017531478A JP2017537940A5 JP 2017537940 A5 JP2017537940 A5 JP 2017537940A5 JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017537940 A5 JP2017537940 A5 JP 2017537940A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537940A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065044 external-priority patent/WO2016094688A1/en
Publication of JP2017537940A publication Critical patent/JP2017537940A/ja
Publication of JP2017537940A5 publication Critical patent/JP2017537940A5/ja
Pending legal-status Critical Current

Links

JP2017531478A 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体 Pending JP2017537940A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090290P 2014-12-10 2014-12-10
US62/090,290 2014-12-10
PCT/US2015/065044 WO2016094688A1 (en) 2014-12-10 2015-12-10 Fused 1,3-azole derivatives useful for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
JP2017537940A JP2017537940A (ja) 2017-12-21
JP2017537940A5 true JP2017537940A5 (OSRAM) 2019-02-07

Family

ID=55073117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531478A Pending JP2017537940A (ja) 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体

Country Status (6)

Country Link
US (2) US10017520B2 (OSRAM)
EP (1) EP3230279A1 (OSRAM)
JP (1) JP2017537940A (OSRAM)
AU (1) AU2015360416A1 (OSRAM)
CA (1) CA2968884A1 (OSRAM)
WO (1) WO2016094688A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SMT202200369T1 (it) 2015-11-19 2022-11-18 Incyte Corp Composti eterociclici come immunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
JP2019505548A (ja) 2016-02-16 2019-02-28 マサチューセッツ インスティテュート オブ テクノロジー Mycモジュレーターとしてのmaxバインダーおよびこれらの使用
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
GB201614134D0 (en) * 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PL3558990T3 (pl) 2016-12-22 2022-12-19 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
BR112021005082A2 (pt) 2018-09-18 2021-06-08 Nikang Therapeutics, Inc. derivados de anel tricíclico fundido como inibidores de src homologia-2 fosfatase
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
EP4103188A4 (en) * 2020-02-10 2024-04-10 StemSynergy Therapeutics, Inc. Myc inhibitors and uses thereof
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
AU6331099A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU2002222683B9 (en) * 2000-12-18 2021-12-23 Institute Of Medicinal Molecular Design, Inc Inflammatory cytokine release inhibitor
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
ATE363278T1 (de) * 2001-09-14 2007-06-15 Novo Nordisk As Neue liganden für die hisb10 zn2+ stellen des insulin-hexamers in der r-konformation
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
AU2003291613B2 (en) * 2002-04-30 2007-09-27 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
ES2530972T3 (es) 2003-09-12 2015-03-09 Elixir Pharmaceuticals Inc Métodos de tratamiento de trastornos
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
WO2006005683A1 (en) * 2004-07-09 2006-01-19 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
PL1746097T3 (pl) * 2005-07-20 2010-06-30 Aventis Pharma Sa Skondensowane heterocykle 1,4-dihydropirydynowe, sposób ich wytwarzania, zastosowanie i zawierające je kompozycje
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
NZ586399A (en) 2008-01-24 2011-12-22 Ucb Pharma Sa Compounds comprising a cyclobutoxy group
CN102016590A (zh) 2008-02-28 2011-04-13 生命技术公司 荧光偏振hERG试验
WO2010054398A1 (en) * 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2010058402A1 (en) * 2008-11-20 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel anti-biofilm agents
WO2010075282A1 (en) 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
CN102078318A (zh) * 2009-11-27 2011-06-01 华东理工大学 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用
WO2011068667A1 (en) * 2009-12-04 2011-06-09 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
CN103209981B (zh) * 2010-09-10 2016-12-28 盐野义制药株式会社 具有ampk活化作用的杂环稠合咪唑衍生物
KR20140093607A (ko) 2011-05-11 2014-07-28 이데미쓰 고산 가부시키가이샤 신규 화합물, 유기 전기발광 소자용 재료 및 유기 전기발광 소자
WO2013038650A1 (ja) 2011-09-13 2013-03-21 出光興産株式会社 縮合複素芳香族誘導体、有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
EP2985278B1 (en) 2013-02-28 2020-01-22 Sumitomo Chemical Company, Limited Fused heterocyclic compound and pest control applications thereof
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US9242944B2 (en) 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
JP6512714B2 (ja) 2013-12-11 2019-05-15 ザ スクリプス リサーチ インスティテュート 低分子C−Myc阻害剤

Similar Documents

Publication Publication Date Title
JP2017537940A5 (OSRAM)
JP2016503797A5 (OSRAM)
JP2018522866A5 (OSRAM)
JP2019514874A5 (OSRAM)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
AR103222A1 (es) Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
JP2015511638A5 (OSRAM)
JP2019524883A5 (OSRAM)
JP2013010792A5 (OSRAM)
JP2015143283A5 (OSRAM)
JP2016515561A5 (OSRAM)
AR099134A1 (es) Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
JP2015537020A5 (OSRAM)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2014511892A5 (OSRAM)
JP2016513130A5 (OSRAM)
JP2016518437A5 (OSRAM)
JP2016540742A5 (OSRAM)
JP2018518537A5 (OSRAM)
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2014508804A5 (OSRAM)
JP2013032389A5 (OSRAM)
JP2010510237A5 (OSRAM)
JP2018522867A5 (OSRAM)
JP2016531126A5 (OSRAM)